A Phase 1 interventional study of BIIB142 and BIIB142-Matching Placebo in Healthy Volunteer, sponsored by Biogen. Recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-06.
Sponsored by Biogen · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
In this study, researchers will learn more about the safety of BIIB142 and how it is processed in the body. This is the first time that researchers will learn about BIIB142 and how it affects people.
The main question researchers want to answer in this study is:
An AE is a health problem that may or may not be caused by a drug during the study. An AE is considered serious when it results in death, is life-threatening, causes lasting problems, or requires hospital care.
Researchers will also learn more about:
This is a "dose escalation study." This is a study in which increasing amounts of the study drug are given to different groups of participants. This is done until researchers find the highest dose that does not cause harmful effects.
First, participants will be screened to check if they can join the study. The screening period will be up to 28 days. This study will be split into 2 parts - Part A and Part B.
During Part A:
During Part B:
The primary objective of this study is to evaluate the safety and tolerability of single and multiple ascending oral doses of BIIB142 in healthy adult participants.
The secondary objective of this study is to evaluate the pharmacokinetics (PK) profile of single and multiple ascending oral doses of BIIB142 in healthy adult participants.
Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.
Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Dose A of BIIB142 or a matching placebo on Day 1 in a fasted state.
Drug: BIIB142 · Drug: BIIB142-Matching Placebo
Participants will receive Dose B of BIIB142 or a matching placebo on Day 1 in a fasted state.
Drug: BIIB142 · Drug: BIIB142-Matching Placebo
Participants will receive Dose C of BIIB142 or a matching placebo on Day 1 in a fasted state.
Drug: BIIB142 · Drug: BIIB142-Matching Placebo
Participants will receive Dose D of BIIB142 or a matching placebo on Day 1 in a fasted state.
Drug: BIIB142 · Drug: BIIB142-Matching Placebo
Participants will receive Dose E of BIIB142 or a matching placebo on Day 1 in a fasted state.
Drug: BIIB142 · Drug: BIIB142-Matching Placebo
Participants will receive BIIB142 on Day 1 in the fasted followed by fed state in the first sequence, and vice versa in the second sequence. A washout period of 14 days will be maintained between both the sequences. Dose will be determined based on emerging PK data.
Drug: BIIB142
Participants will receive Dose A of BIIB142 or a matching placebo administered orally once daily for 14 days in a fasted state.
Drug: BIIB142 · Drug: BIIB142-Matching Placebo
Participants will receive Dose F of BIIB142 or a matching placebo administered orally once daily for 14 days in a fasted state.
Drug: BIIB142 · Drug: BIIB142-Matching Placebo
Participants will receive Dose D of BIIB142 or a matching placebo administered orally once daily for 14 days in a fasted state.
Drug: BIIB142 · Drug: BIIB142-Matching Placebo
Administered Orally
Administered Orally
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: Part A (SAD): Up to Day 15; Part B (MAD): Up to Day 29
Number of Participants with Clinical Laboratory Abnormalities
Time frame: Part A (SAD): Up to Day 15; Part B (MAD): Up to Day 29
Number of Participants with Potentially Clinically Relevant Abnormalities in Vital Sign Parameters
Time frame: Part A (SAD): Up to Day 15; Part B (MAD): Up to Day 29
Number of Participants With Change From Baseline in Columbia Suicide Severity Rating Scale (C-SSRS) Score
Time frame: Part B (MAD): Up to Day 29
Number of Participants With Potentially Clinically Relevant Abnormalities in 12-lead Electrocardiogram (ECG) Parameters
Time frame: Part A (SAD): Up to Day 15; Part B (MAD): Up to Day 29
Plasma Concentration of BIIB142
Time frame: Pre-dose and at multiple timepoints post-dose [Part A (SAD): Up to Day 15; Part B (MAD): Up to Day 29]
Area Under the Concentration-Time Curve (AUC) of BIIB142
Time frame: Pre-dose and at multiple timepoints post-dose [Part A (SAD): Up to Day 15; Part B (MAD): Up to Day 29]
Maximum Observed Concentration (Cmax) of BIIB142
Time frame: Pre-dose and at multiple timepoints post-dose [Part A (SAD): Up to Day 15; Part B (MAD): Up to Day 29]
Time to Maximum Observed Concentration (Tmax) of BIIB142
Time frame: Pre-dose and at multiple timepoints post-dose [Part A (SAD): Up to Day 15; Part B (MAD): Up to Day 29]
Apparent Clearance (CL/F) of BIIB142
Time frame: Pre-dose and at multiple timepoints post-dose [Part A (SAD): Up to Day 15; Part B (MAD): Up to Day 29]
Apparent Volume of Distribution (Vz/F) of BIIB142
Time frame: Pre-dose and at multiple timepoints post-dose [Part A (SAD): Up to Day 15; Part B (MAD): Up to Day 29]
Elimination Half-Life (t1/2) of BIIB142
Time frame: Pre-dose and at multiple timepoints post-dose [Part A (SAD): Up to Day 15; Part B (MAD): Up to Day 29]
Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Aug 2026, 11 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.